Biocon to start selling breast cancer drug in India in February

MUMBAI Sat Jan 18, 2014 3:34pm IST

Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon Ltd, speaks during the Reuters India Investment Summit in Bangalore December 6, 2007. REUTERS/Arko Datta/Files

Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon Ltd, speaks during the Reuters India Investment Summit in Bangalore December 6, 2007.

Credit: Reuters/Arko Datta/Files

Related Topics

Stocks

   
Priyanka Gandhi Vadra, daughter of Congress party chief Sonia Gandhi, adjusts her flower garlands as she campaigns for her mother during an election meeting at Rae Bareli in Uttar Pradesh April 22, 2014. REUTERS/Pawan Kumar

Election 2014

More than 814 million people — a number larger than the population of Europe — are eligible to vote in the world’s biggest democratic exercise.  Full Coverage 

MUMBAI (Reuters) - Biocon Ltd(BION.NS) said its generic version of Roche's(ROG.VX) Herceptin breast cancer treatment would be available to patients in India from the first week of February.

Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with U.S.-based Mylan Inc.

About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.

Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drugmakers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.

Global sales for Herceptin were valued at about $6.4 billion in 2012, including about $21 million in India, Biocon said.

(Reporting by Aradhana Aravindan; Editing by Sonya Hepinstall)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Asian Markets

Asian Markets

Asian stocks flat after China PMI meets expectations  Full Article 

Chinese Economy

Chinese Economy

Factory activity shrinks for 4th month; pace of decline slows   Full Article 

International Gold

International Gold

Gold hovers near 2-1/2 month lows on firm equities, fund outflows  Full Article 

GM Lawsuit

GM Lawsuit

GM seeks U.S. court protection against ignition lawsuits  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage